http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
탄소섬유판 (CFRP) 표면매립 (NSM) 공법을 이용한 콘크리트 구조물 휨 보강에 관한 실험 연구
임동환,Lim, Dong Hwan 대한토목학회 2013 대한토목학회논문집 Vol.33 No.1
본 연구에서는 탄소섬유판을 콘크리트 표면에 매립하는 표면매립(NSM) 공법을 적용하여 콘크리트 구조물 보강을 수행하고, 콘크리트 내구성 증진 뿐 아니라 구조물 수명을 향상 시킬 수 있는 노후구조물 보수 보강 체계를 구축하고자 하였다. 이를 위하여, 표면매립 탄소섬유판 및 고성능 단면복구 모르터로 보강된 철근 콘크리트 부재를 제작하여 실험을 수행하였다. 실험결과, 에폭시로 탄소섬유판을 매립 부착한 철근콘크리트 부재는 보강되지 않은 부재보다 초기 강성 및 휨강도가 현저하게 증가하는 것으로 나타났다. 탄소섬유판으로 보강된 철근콘크리트 부재는 탄소섬유판의 인장 파괴로 인하여 시작되며, 탄소섬유판의 저항능력은 매우 우수하며, 보강 효율이 우수한 것으로 나타났다. 탄소섬유판을 매립하고 표면부에 고성능 모르터로 단면을 복구하는 보강 방식은 보의 강성 및 내구성을 향상시킬 뿐 아니라 미관이 우수하여 보수와 보강이 혼합된 적절한 보강 방식으로 판단된다. The purpose of this study is to establish the flexural strengthening method of the concrete members. To accomplish this objective, a total of seven concrete beams were tested. From this study, it is found that the initial flexural stiffness and strength of the beams reinforced with NSM CFRP strips were significantly improved compared to the beam without CFRP strip. Failure of the beam reinforced with NSM strips is initiated by failure of NSM strips, eventually sudden explosive compressive failure in the loaded region. This strengthening method combined with NSM CFRP strips and high performance mortar for concrete cover recovery is evaluated by a good strengthening method for the strength, durability and good appearance of concrete structures.
임상 : 악성뇌교종의 항암 및 방사선 병합치료의 효과와 독성
임동환 ( Dong Hwan Lim ),전신수 ( Shin Soo Jeun ),박춘근 ( Chun Geun Park ),강준기 ( Joon Gi Kang ),김문찬 ( Moon Chan Kim ),홍용길 ( Yong Kil Hong ) 대한뇌종양학회 2005 대한뇌종양학회지 Vol.4 No.1
Objective£ºConcurrent chemotherapy and radiotherapy trials have been reported to increase anti-tumoral effect and toxicity in several solid cancers, but little has been known in brain tumors. We analyzed clinical efficacy and toxicity of the concurrent therapy as a first line modality in malignant glioma patients. Methods£ºFrom March 1998 to December 2003, twenty- five patients were enrolled in this study. They are composed of 11 glioblastomas(GBM), 8 anaplastic astrocytomas(AA), 5 anaplastic oligodendrogliomas(AO), and 1 anaplastic oligoastrocytoma(AOA). Mean age was 45.3(19-67) years old with 14 females and 11 males. Both radiotherapy and chemotherapy, composed of BCNU(120mg/m2) or CCNU(75-110mg/m2), procarbazine(60mg/m2) and vincristine(1.4 mg/m2), started simultaneously within 2 weeks after surgery. Results£ºMedian progression-free survival time(PFS) was 9 months for the patients with GBM, and 19 months for the patients with Non-GBM. Grade III/IV leukopenia developed in 7 of 25(28%) patients and thrombocytopenia in 2 of 25 (8%). Radiation necrosis occurred in 3 patients(12%). Conclusion£ºConcurrent chemoradiotherapy improved PFS in high-grade glioma patients and its toxicity was tolerable. These preliminary results suggest that further studies would be warranted to improve the clinical efficacy of this therapy in malignant gliomas.